Loading...

APVO APTEVO THERAPEUTICS INC Expansion Plans 8-K Filing

PTV

PV

APTEVO THERAPEUTICS INC

(APVO)

2025 8-K

Financial Results Announcement

New Clinical Data

Stockholder Meeting

Management Transition

Equity Purchase Agreement

Stock Split Approved

Positive Trial Results

Financial Results

Rights Agreement Update

Clinical Trial Success

Pipeline Expansion

Equity Offerings

Equity Offerings

Management Changes

Equity Offerings

Equity Offerings

Equity Offerings

Reverse Stock Split

Failure to Maintain Listing

Financial Statements

Equity Offerings

Equity Offerings

Financial Results

Investor Presentation

Warrant Agreement

New Antibody Announcement

Conference Announcement

Cancer Immunotherapy

Financial Results

Rights Agreement Amendment

Stockholder Meeting

Securities Offering

Financial Results Announcement

Meeting of Stockholders

Delisting Notice

Registered Direct Offering

Annual Meeting of Stockholders

Financial Results Announcement

Public Offering

Interim Data Announcement

Reverse Stock Split

Financial Results Announcement

Special Meeting of Stockhol...

Financial Results Announcement

Warrant Inducement Agreement

Amendment to Rights Agreement

Earnings Report

Public Offering

Product Updates

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Material Definitive Agreement

Management Appointments

Phase 1 Trial Announcement

External Links:

On December 9, 2025, Aptevo Therapeutics Inc. announced promising safety and high remission rates for mipletamig in treating frontline acute myeloid leukemia at the ASH 2025 conference. The positive data was from its Phase 1b/2 RAINIER trial, specifically for patients unfit for intensive chemotherapy.

AI Assistant

APTEVO THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.